---
title: "Dasatinib-Loaded HSA Nanoparticle Hydrogel for Localised Eradication of Residual Melanoma"
id: "pubmed-42606056"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42606056"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42606056/"
doi: "10.1021/acsabm.6c00772"
published_at: "2026-08-17T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Dasatinib-Loaded HSA Nanoparticle Hydrogel for Localised Eradication of Residual Melanoma
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42606056
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42606056/)
- **DOI:** [10.1021/acsabm.6c00772](https://doi.org/10.1021%2Facsabm.6c00772)
- **Published At:** 2026-08-17T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- Study repurposed **Dasatinib (DAS)**, an antineoplastic agent approved for chronic myeloid leukemia, to target residual post-surgical **melanoma** cells using a topical biomacromolecule delivery system. - Dasatinib was encapsulated in **human serum albumin (HSA) nanoparticles** (DNPs) optimized by a Box-Behnken design and subsequently incorporated into a hydrogel for localized application. - Optimized DNP characteristics: particle size 125.6 ± 1.58 nm, polydispersity index (PDI) 0.242 ± 0.008, and zeta potential −14.28 ± 0.22 mV. - Solid-state and chemical analyses (ATR-FTIR, PXRD, DSC) indicated **amorphisation** of Dasatinib in DNPs and no chemical interactions between drug and carrier. - Drug loading and entrapment efficiencies were reported as 7.49 ± 0.28% and 89.80 ± 1.52%, respectively. - In vitro functional evaluations included MTT cytotoxicity assays, scratch (migration) assays, transwell invasion assays, cell cycle analysis, and 3D tumoroid/spheroid assays; DNPs showed superior cytotoxic, anti-invasion, and anti-migration activity compared with controls. - Mechanistic studies attributed DNP-induced apoptosis to **caspase-7 upregulation** and concomitant downregulation of pro-survival and pro-angiogenic markers: **PI3K, p-mTOR, VEGFR, and EGFR**. - Dermatokinetic testing of the DNP-loaded hydrogel demonstrated accumulation of nanoparticles in the epidermal and dermal layers proximal to residual melanoma cells, supporting localized retention and potential therapeutic effect. - Authors conclude that the **DNP-entrapped hydrogel** shows promise as a topical strategy to manage residual melanoma by delivering repurposed Dasatinib to skin layers where microscopic disease persists.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42606056/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42606056%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42606056/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42606056/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42606056/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/af7de7da-df5d-41c6-8de4-8c266af8ccfb/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42606056/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42606056/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42606056/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42606056%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42606056%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42606056/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42606056/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42606056/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42606056/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42606056/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42606056/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42606056/#abstract) * [Similar articles](https://pubmed.ncbi.nlm.nih.gov/42606056/#similar) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42606056/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42606056/#substances) * [ Grants and funding ](https://pubmed.ncbi.nlm.nih.gov/42606056/#grants) Title & authors Abstract Similar articles MeSH terms Substances Grants and funding ACS Appl Bio Mater Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22ACS+Appl+Bio+Mater%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22ACS+Appl+Bio+Mater%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42606056/) . 2026 Aug 17;9(16):7512-7536. doi: 10.1021/acsabm.6c00772. # Dasatinib-Loaded Human Serum Albumin Nanoparticle-Impregnated Hydrogel for Localised Eradication of Residual Melanoma: Integrated In Silico, 3D Spheroid, and Dermatokinetic Evaluation [Ganesh Vambhurkar](https://pubmed.ncbi.nlm.nih.gov/?term=Vambhurkar+G&cauthor_id=42606056)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42606056/#full-view-affiliation-1 "Pharmaceutical Innovation and Translational Research Lab \(PITRL\), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research \(NIPER\), Hyderabad, Telangana500037, India."), [Paras Famta](https://pubmed.ncbi.nlm.nih.gov/?term=Famta+P&cauthor_id=42606056)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42606056/#full-view-affiliation-1 "Pharmaceutical Innovation and Translational Research Lab \(PITRL\), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research \(NIPER\), Hyderabad, Telangana500037, India."), [Saurabh Shah](https://pubmed.ncbi.nlm.nih.gov/?term=Shah+S&cauthor_id=42606056)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42606056/#full-view-affiliation-1 "Pharmaceutical Innovation and Translational Research Lab \(PITRL\), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research \(NIPER\), Hyderabad, Telangana500037, India."), [Rahul Kumar](https://pubmed.ncbi.nlm.nih.gov/?term=Kumar+R&cauthor_id=42606056)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42606056/#full-view-affiliation-2 "Department of Biological Sciences, National Institute of Pharmaceutical Education and Research \(NIPER\), Hyderabad, Telangana500037, India."), [Anamika Sharma](https://pubmed.ncbi.nlm.nih.gov/?term=Sharma+A&cauthor_id=42606056)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42606056/#full-view-affiliation-2 "Department of Biological Sciences, National Institute of Pharmaceutical Education and Research \(NIPER\), Hyderabad, Telangana500037, India."), [Abhishek Sharma](https://pubmed.ncbi.nlm.nih.gov/?term=Sharma+A&cauthor_id=42606056)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42606056/#full-view-affiliation-1 "Pharmaceutical Innovation and Translational Research Lab \(PITRL\), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research \(NIPER\), Hyderabad, Telangana500037, India."), [Niharika Puri](https://pubmed.ncbi.nlm.nih.gov/?term=Puri+N&cauthor_id=42606056)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42606056/#full-view-affiliation-1 "Pharmaceutical Innovation and Translational Research Lab \(PITRL\), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research \(NIPER\), Hyderabad, Telangana500037, India."), [Gurpreet Singh](https://pubmed.ncbi.nlm.nih.gov/?term=Singh+G&cauthor_id=42606056)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42606056/#full-view-affiliation-2 "Department of Biological Sciences, National Institute of Pharmaceutical Education and Research \(NIPER\), Hyderabad, Telangana500037, India."), [Etikala Amulya](https://pubmed.ncbi.nlm.nih.gov/?term=Amulya+E&cauthor_id=42606056)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42606056/#full-view-affiliation-1 "Pharmaceutical Innovation and Translational Research Lab \(PITRL\), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research \(NIPER\), Hyderabad, Telangana500037, India."), [Suraj Wagh](https://pubmed.ncbi.nlm.nih.gov/?term=Wagh+S&cauthor_id=42606056)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42606056/#full-view-affiliation-1 "Pharmaceutical Innovation and Translational Research Lab \(PITRL\), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research \(NIPER\), Hyderabad, Telangana500037, India."), [Anupama Sikder](https://pubmed.ncbi.nlm.nih.gov/?term=Sikder+A&cauthor_id=42606056)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42606056/#full-view-affiliation-1 "Pharmaceutical Innovation and Translational Research Lab \(PITRL\), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research \(NIPER\), Hyderabad, Telangana500037, India."), [Nitin Pal Kalia](https://pubmed.ncbi.nlm.nih.gov/?term=Kalia+NP&cauthor_id=42606056)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42606056/#full-view-affiliation-2 "Department of Biological Sciences, National Institute of Pharmaceutical Education and Research \(NIPER\), Hyderabad, Telangana500037, India."), [Saurabh Srivastava](https://pubmed.ncbi.nlm.nih.gov/?term=Srivastava+S&cauthor_id=42606056)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42606056/#full-view-affiliation-1 "Pharmaceutical Innovation and Translational Research Lab \(PITRL\), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research \(NIPER\), Hyderabad, Telangana500037, India.") Affiliations Expand ### Affiliations * 1 Pharmaceutical Innovation and Translational Research Lab (PITRL), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana500037, India. * 2 Department of Biological Sciences, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana500037, India. * PMID: **42606056** * DOI: [ 10.1021/acsabm.6c00772 ](https://doi.org/10.1021/acsabm.6c00772) Item in Clipboard # Dasatinib-Loaded Human Serum Albumin Nanoparticle-Impregnated Hydrogel for Localised Eradication of Residual Melanoma: Integrated In Silico, 3D Spheroid, and Dermatokinetic Evaluation Ganesh Vambhurkar et al. ACS Appl Bio Mater. 2026. Show details Display options Display options Format Abstract PubMed PMID ACS Appl Bio Mater Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22ACS+Appl+Bio+Mater%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22ACS+Appl+Bio+Mater%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42606056/) . 2026 Aug 17;9(16):7512-7536. doi: 10.1021/acsabm.6c00772. ### Authors [Ganesh Vambhurkar](https://pubmed.ncbi.nlm.nih.gov/?term=Vambhurkar+G&cauthor_id=42606056)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42606056/#short-view-affiliation-1 "Pharmaceutical Innovation and Translational Research Lab \(PITRL\), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research \(NIPER\), Hyderabad, Telangana500037, India."), [Paras Famta](https://pubmed.ncbi.nlm.nih.gov/?term=Famta+P&cauthor_id=42606056)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42606056/#short-view-affiliation-1 "Pharmaceutical Innovation and Translational Research Lab \(PITRL\), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research \(NIPER\), Hyderabad, Telangana500037, India."), [Saurabh Shah](https://pubmed.ncbi.nlm.nih.gov/?term=Shah+S&cauthor_id=42606056)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42606056/#short-view-affiliation-1 "Pharmaceutical Innovation and Translational Research Lab \(PITRL\), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research \(NIPER\), Hyderabad, Telangana500037, India."), [Rahul Kumar](https://pubmed.ncbi.nlm.nih.gov/?term=Kumar+R&cauthor_id=42606056)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42606056/#short-view-affiliation-2 "Department of Biological Sciences, National Institute of Pharmaceutical Education and Research \(NIPER\), Hyderabad, Telangana500037, India."), [Anamika Sharma](https://pubmed.ncbi.nlm.nih.gov/?term=Sharma+A&cauthor_id=42606056)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42606056/#short-view-affiliation-2 "Department of Biological Sciences, National Institute of Pharmaceutical Education and Research \(NIPER\), Hyderabad, Telangana500037, India."), [Abhishek Sharma](https://pubmed.ncbi.nlm.nih.gov/?term=Sharma+A&cauthor_id=42606056)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42606056/#short-view-affiliation-1 "Pharmaceutical Innovation and Translational Research Lab \(PITRL\), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research \(NIPER\), Hyderabad, Telangana500037, India."), [Niharika Puri](https://pubmed.ncbi.nlm.nih.gov/?term=Puri+N&cauthor_id=42606056)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42606056/#short-view-affiliation-1 "Pharmaceutical Innovation and Translational Research Lab \(PITRL\), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research \(NIPER\), Hyderabad, Telangana500037, India."), [Gurpreet Singh](https://pubmed.ncbi.nlm.nih.gov/?term=Singh+G&cauthor_id=42606056)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42606056/#short-view-affiliation-2 "Department of Biological Sciences, National Institute of Pharmaceutical Education and Research \(NIPER\), Hyderabad, Telangana500037, India."), [Etikala Amulya](https://pubmed.ncbi.nlm.nih.gov/?term=Amulya+E&cauthor_id=42606056)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42606056/#short-view-affiliation-1 "Pharmaceutical Innovation and Translational Research Lab \(PITRL\), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research \(NIPER\), Hyderabad, Telangana500037, India."), [Suraj Wagh](https://pubmed.ncbi.nlm.nih.gov/?term=Wagh+S&cauthor_id=42606056)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42606056/#short-view-affiliation-1 "Pharmaceutical Innovation and Translational Research Lab \(PITRL\), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research \(NIPER\), Hyderabad, Telangana500037, India."), [Anupama Sikder](https://pubmed.ncbi.nlm.nih.gov/?term=Sikder+A&cauthor_id=42606056)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42606056/#short-view-affiliation-1 "Pharmaceutical Innovation and Translational Research Lab \(PITRL\), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research \(NIPER\), Hyderabad, Telangana500037, India."), [Nitin Pal Kalia](https://pubmed.ncbi.nlm.nih.gov/?term=Kalia+NP&cauthor_id=42606056)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42606056/#short-view-affiliation-2 "Department of Biological Sciences, National Institute of Pharmaceutical Education and Research \(NIPER\), Hyderabad, Telangana500037, India."), [Saurabh Srivastava](https://pubmed.ncbi.nlm.nih.gov/?term=Srivastava+S&cauthor_id=42606056)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42606056/#short-view-affiliation-1 "Pharmaceutical Innovation and Translational Research Lab \(PITRL\), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research \(NIPER\), Hyderabad, Telangana500037, India.") ### Affiliations * 1 Pharmaceutical Innovation and Translational Research Lab (PITRL), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana500037, India. * 2 Department of Biological Sciences, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana500037, India. * PMID: **42606056** * DOI: [ 10.1021/acsabm.6c00772 ](https://doi.org/10.1021/acsabm.6c00772) Item in Clipboard Cite Display options Display options Format Abstract PubMed PMID ## Abstract The aim of this study is to investigate active targeting of residual melanoma cells. Melanoma is the most aggressive form of skin cancer for which the conventional therapies often fail to target post-surgical residual cells owing to challenges like chemoresistance, early metastasis, and recurrence. To mitigate the following issues, we repurposed Dasatinib (DAS), an antineoplastic drug approved for chronic myeloid leukaemia, and evaluated its potential in melanoma treatment through a safe, biomacromolecule-based topical delivery system. DAS-loaded human serum albumin nanoparticles (DNPs) were optimised via Box-Behnken design and incorporated into a hydrogel for localised delivery. The DNPs had a particle size of 125.6 ± 1.58 nm with a polydispersity index of 0.242 ± 0.008 and a zeta potential of -14.28 ± 0.22 mV. ATR-FTIR, PXRD, and DSC analyses demonstrated amorphisation of the drug in DNPs devoid of any chemical interactions. The loading and entrapment efficiencies of DAS in DNPs were estimated to be 7.49 ± 0.28 and 89.80 ± 1.52%, respectively. In vitro assays such as the MTT assay, scratch assay, transwell-based invasive assays, cell cycle assay, and 3D tumoroid-based assays demonstrated superior cytotoxic, anti-invasion, and antimigration properties of DNPs. Mechanistic studies demonstrated that DNPs induced apoptosis via caspase-7 upregulation and downregulation of PI3K, p-mTOR, VEGFR, and EGFR. Dermatokinetic analysis of DNPs-entrapped hydrogel confirmed DNPs accumulation in the epidermal and dermal layers near residual melanoma cells, highlighting their therapeutic potential in the management of residual disease. **Keywords:** Dasatinib; HSA nanoparticles; dermatokinetics; melanoma; topical delivery. © 2026 American Chemical Society. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Similar articles * [ Thermosensitive Block Copolymer Hydrogel with Embedded Catanionic Vesicles as a Localized Doxorubicin Delivery Platform for Melanoma. ](https://pubmed.ncbi.nlm.nih.gov/42504495/) Machado RL, Zoco A, Oliveira IS, Silva B, Gomes AC, Marques EF.Machado RL, et al.ACS Appl Bio Mater. 2026 Aug 17;9(16):7467-7485. doi: 10.1021/acsabm.6c00633.ACS Appl Bio Mater. 2026.PMID: 42504495 * [ Drug loaded hydrogel nanoparticles with long retention in tumor and multi drug co delivery for melanoma treatment. ](https://pubmed.ncbi.nlm.nih.gov/40690894/) Bai J, Liu Y, Chen X, Wang L, Shi J, Liu H, Peng W, Zhao Y, Weng J, Zhi W, Wang J.Bai J, et al.Colloids Surf B Biointerfaces. 2025 Nov;255:114962. doi: 10.1016/j.colsurfb.2025.114962. Epub 2025 Jul 17.Colloids Surf B Biointerfaces. 2025.PMID: 40690894 * [ Development and evaluation of nilotinib-loaded Bovine Serum Albumin nanoparticles: In-vitro and in-silico insights. ](https://pubmed.ncbi.nlm.nih.gov/40154676/) Shaikh S, Chary PS, Khan O, Mehra NK.Shaikh S, et al.Int J Biol Macromol. 2025 May;308(Pt 4):142185. doi: 10.1016/j.ijbiomac.2025.142185. Epub 2025 Mar 26.Int J Biol Macromol. 2025.PMID: 40154676 * [ Therapeutic Potential of Silver
## Related Clinical Research

- [Thermosensitive Hydrogel with Catanionic Vesicles for Localized Doxorubicin Delivery in Melanoma](https://medichelpline.com/clinical-feed/pubmed-42504495.md) (DOI: 10.1021/acsabm.6c00633)
- [Personalized mRNA vaccine plus pembrolizumab lowers melanoma recurrence in phase 3 trial](https://medichelpline.com/clinical-feed/medical-news-today-0-novel-mrna-vaccine-plus-immunotherapy-reduces-melanoma-relapse-in-phase-3-trial.md)
- [Arginine supplements and immune recognition: mouse study links arginine to improved cancer and vir](https://medichelpline.com/clinical-feed/medical-news-today-0-could-arginine-supplements-help-boost-immune-responses-to-cancer-viruses.md)
- [Gene-based immunotherapy in osteosarcoma: full article text not available on source page](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-gene-based-immunotherapy-in-osteosarcoma-from-oncolytic-vectors-to-engineered.md)
- [Pyrazolo[3,4-b]pyridine chemotype as a dual FAK1/FAK2 inhibitor for triple-negative breast cancer](https://medichelpline.com/clinical-feed/pubmed-42172799.md) (DOI: 10.1016/j.bioorg.2026.110005)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.